Eli Lilly’s Abemaciclib Combo Pushes Deeper Into Advanced Prostate Cancer

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study.

The Phase 1b study “A Phase 1b Study of Abemaciclib Plus Darolutamide in Men With Metastatic Castration-Resistant Prostate Cancer” tests a new drug mix in hard to treat prostate cancer. It aims to see if adding Eli Lilly’s abemaciclib to darolutamide can offer a safer, more effective option after standard care has failed.

The trial evaluates abemaciclib, an oral cancer pill, combined with darolutamide, an oral hormone blocker used in advanced prostate cancer. The goal is to check how well this combo is tolerated and whether it can better control tumors that keep growing despite hormone therapy.

This is an interventional study with one treatment group only, so every patient gets the drug mix. There is no placebo and no blinding, which makes results easier to interpret but also means there is no direct comparison arm.

The study’s primary purpose is treatment, not prevention or diagnosis. As a Phase 1b trial, the focus is safety and dose insights rather than clear proof of benefit, but any strong signals could justify larger, later-stage studies.

The study was first submitted on August 14, 2023, marking the formal start of regulatory tracking. It has now reached a “Completed” status, meaning patient dosing and main data collection are done.

The latest update was filed on March 2, 2026, signaling that Eli Lilly has refreshed key details, likely as data cleaning and analysis advance. No results have been posted yet, so the market is still waiting on concrete safety and activity numbers.

For investors, this completed Phase 1b trial is a small but useful catalyst for Eli Lilly as it explores oncology beyond its high profile weight loss and diabetes franchises. Any hint that abemaciclib can extend its reach into tougher prostate cancer settings could support long term growth narratives.

Bayer’s role as collaborator through darolutamide is also notable, as success could strengthen its oncology revenue base. In a crowded prostate cancer field with AstraZeneca, Pfizer and others, positive combination data could open new label or lifecycle extension paths if later phases confirm the signal.

Near term stock impact for LLY is likely modest, given the early stage and lack of posted results, but sentiment could firm as investors see a broader cancer pipeline beyond existing breast cancer use. The key inflection will come when top line safety and early activity readouts appear and the companies decide on larger follow up trials.

This study is now completed and has been recently updated, with further details and future data releases to be tracked on the ClinicalTrials.gov portal under NCT05999968.

To learn more about LLY’s potential, visit the Eli Lilly And Company drug pipeline page.